Theranostic applications of antibodies in oncology

Emmy D G Fleuren1, Yvonne M H Versleijen-Jonkers1, Sandra Heskamp2

  • 1Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Molecular Oncology
|April 15, 2014
PubMed

Insights

Theranostic antibodies personalize cancer treatment by combining diagnosis and therapy. This approach improves patient selection and monitoring, overcoming limitations of current antibody therapies.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Imaging

Background:

  • Antibody therapies are crucial in cancer treatment but face limitations like patient specificity and acquired resistance.
  • Accurate patient selection and response monitoring are essential due to therapy costs and side effects.
  • Theranostics offer a solution by integrating diagnostic and therapeutic antibody functions for personalized treatment.

Purpose of the Study:

  • To review the clinical applications of theranostic antibodies in oncology.
  • To assess the suitability of antibodies for theranostic development.
  • To summarize current clinical efficacy and future directions for antibody theranostics.

Main Methods:

  • Review of clinical applications and efficacy data for theranostic antibodies.
  • Analysis of theranostic test types and antibody suitability.
  • Discussion of advanced applications like radiolabeled antibodies for imaging.

Main Results:

  • Theranostic antibodies enhance patient selection for targeted cancer therapy.
  • They enable monitoring of treatment response and acquired resistance.
  • Radiolabeled antibodies facilitate non-invasive functional imaging.

Conclusions:

  • Theranostic antibodies are vital for personalized medicine in oncology.
  • They improve the efficacy and safety of antibody-based cancer treatments.
  • Future research should focus on optimizing the application of antibody theranostics.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.2K
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.9K